Werkgroep Cardiologische centra Nederland

MariTime HF (Recruiting)

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure
Medicine
Meridebart Cafraglutide
Population
Heart failure
Phase
III
Starting year
2024

Director of Study

dr. C.A. da Fonseca (Cardioloog)
Leeuwarden, FrisiusMC